Veradermics VDPHL01: why isn’t anyone talking about it? Treatment 12/14/2024
Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity 6 months before and after pics: VDPHL01 (oral minoxidil)
A user shared their positive experience with a clinical trial for a new oral medication, VDPHL01, which is a reformulated version of oral minoxidil taken at a high dose of 17mg daily, showing significant hair regrowth after six months. The user noted that this formulation is believed to be more effective and time-released, with fewer side effects compared to regular oral minoxidil.
community Veradermics VDPHL01 Topline Results for Extended-Release Oral Minoxidil
Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.
community Rejected for the 2nd time for the VDPHL01 Clinical Trials (believe it or not!)
The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.
community How Veradermics secured a total of $220 million in series B and C financing for oral minoxidil, I will never understand.....
Veradermics' oral minoxidil shows promise for hair regrowth, with some users reporting significant improvements, while Pelage's PP405 results are less convincing and lack transparency. There is skepticism about both treatments' long-term effectiveness and potential side effects.
community VDPHL-01 is Overrated and Ridiculous. This is just Oral Minoxidil.
VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.
Related Research
6 / 6 results
research Emerging pharmacotherapies and regenerative solutions for promoting hair growth for androgenetic alopecia
This study reviews new treatments for androgenetic alopecia, including cell-derived exosomes and investigational drugs, which show potential to improve hair density and quality but require more rigorous and standardized trials to confirm efficacy and safety.
research Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA
This study reported that ritlecitinib was prescribed to a diverse group of patients with severe alopecia areata in the first 10 months after FDA approval, indicating its potential role in AA management.
research Evaluating the Quality of TikTok Content on Alopecia: A Cross-Sectional DISCERN-Based Analysis
This study found that alopecia-related content on TikTok is generally low in quality, with dermatologist-created videos being higher quality but receiving less engagement compared to personal experience videos.
research The Intersection of Sleep and Hair Loss: A Systematic Review
This study suggests a possible bidirectional relationship between sleep quality and hair loss, indicating that addressing sleep disturbances might improve hair loss management and patient well-being.
research A Systematic Literature Review of Alopecia Areata in Children and Adolescents: Psychosocial Impact
This review highlights the significant psychosocial impact of alopecia areata on children and adolescents, affecting self-esteem, relationships, academic performance, and the well-being of their families.
research Emerging pharmacotherapies for Androgenetic Alopecia
This article reviews emerging therapies for androgenetic alopecia, highlighting advances like androgen-receptor antagonists and improved minoxidil delivery that aim to enhance treatment efficacy and safety.